TZTao Zuo

Tao Zuo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tao Zuo has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Ping Xu

    State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Beijing Institute of Lifeomics, Beijing 102206, China

    7 shared publications
  • Lei Chang

    State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences

    4 shared publications
  • Feng Xu

    State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), Research and Development of New Drug of Chinese Academy of Medical Sciences

    3 shared publications
  • Kaixuan Li

    State Key Laboratory of Medical Proteomics, National Center for Protein Sciences, Research Unit of Proteomics and Research and Development of New Drug of Chinese Academy of Medical Sciences, Beijing Proteome Research Center, Institute of Lifeomics, Medical School of Chinese People’s Liberation Army (PLA), Faculty of Hepato‑Pancreato‑Biliary Surgery, Chinese PLA General Hospital, Beijing, China

    3 shared publications
  • Lei Chang

    State Key Laboratory of Medical Proteomics, National Center for Protein Sciences, Research Unit of Proteomics and Research and Development of New Drug of Chinese Academy of Medical Sciences, Beijing Proteome Research Center, Institute of Lifeomics, Medical School of Chinese People’s Liberation Army (PLA), Faculty of Hepato‑Pancreato‑Biliary Surgery, Chinese PLA General Hospital, Beijing, China

    3 shared publications
  • Shu Liu

    State Key Laboratory of Medical Proteomics, National Center for Protein Sciences, Research Unit of Proteomics and Research and Development of New Drug of Chinese Academy of Medical Sciences, Beijing Proteome Research Center, Institute of Lifeomics, Medical School of Chinese People’s Liberation Army (PLA), Faculty of Hepato‑Pancreato‑Biliary Surgery, Chinese PLA General Hospital, Beijing, China

    3 shared publications

Latest Publications

  • Exosomal Proteome from Hepatocellular Carcinoma Patient-Derived Xenograft Mice Serves as Identity of Liver Cancer

    by Tao Zuo, Peiru Chen, Zhenpeng Zhang, Mingsong Mao, Yuan Li, Zilin Li, Xin Feng, Yihao Wang, Zhen Sun, Fenglong Jiao, et al.

    Hepatocellular carcinoma (HCC) constitutes approximately 90% of liver cancers, yet its early detection remains challenging due to the low sensitivity of current diagnostic methods and the difficulty in identifying minimal cancer cells within the body. This study employed a patient-derived xenograft (PDX) mouse model to screen for biomarkers, leveraging its advantage of low background interference compared to human serum exosome studies. Using a novel microextraction technique, exosomes were isolated from just one microliter of serum from HCC PDX mice, followed by proteomic profiling. Analysis revealed that serum exosomal proteins from PDX mice were enriched in cancer-related pathways. The exosomal proteome not only distinguished PDX mice from controls but also differentiated between individual PDX groups, supporting its use as a tumor-specific identifier (tumor ID) and a noninvasive tool for monitoring tumors. Bioinformatics identified a panel of serum exosomal protein biomarkers predictive of HCC patient outcomes, which were validated via targeted proteomics and array-based high-throughput detection. These upregulated biomarkers in HCC patients positively correlate with disease severity and poor prognosis, underscoring their clinical potential.


  • Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets

    by Ze Zhang, Zhenpeng Zhang, Yao Zhang, Yuan Li, Kaixuan Li, Shu Liu, Junning Cao, Yanchang Li, Xuehui Peng, Suzhen Li, et al.

    Background & Aims: Only a minority of patients could benefit from systemic therapy owing to the high heterogeneity of HCC. Therefore, a deeper understanding of the pathogenesis of HCC is essential for precision therapy. Genomic and proteomic studies of HCC have enhanced our understanding of HCC. However, phosphoproteomic characterization of HCC remains poorly understood. Approach & Results: We conducted an in-depth analysis of a clinical cohort of HCC using high-coverage phosphoproteomic. Effective therapeutic targets were validated using liver cancer cell lines and HCC patient-derived xenograft (PDX) mouse models that correspond to the phosphoproteomic subtypes of HCC. Phosphoproteomic analysis classified HCC into three subtypes, A, B, and C, with increasing malignancy and correlation with clinical features, including patient prognosis, tumor staging, serum alpha fetoprotein (AFP) levels, tumor thrombus, and tumor size. Phosphoproteomic subtyping deeply reflected the biological characteristics and clinical features of HCC patients. The profiles of HCC dysregulated kinase activities inferred from the different phosphoproteomic subtypes, consistently identifying increased kinase activity related to cell proliferation. Subtype-C HCC patients showed the most significant dysregulation, indicating a potential therapeutic target. The corresponding drug, bosutinib, demonstrated efficacy in inhibiting the growth of subtype C tumors in liver cancer cell lines and HCC patient-derived xenograft (PDX) mouse models representative of the phosphoproteomic HCC subtypes. Conclusions: Our study provides a comprehensive exploration of the phosphoproteomic landscape of HCC, establishing new subtypes that match clinical features and identifying potential therapeutic targets for the most malignant C subtype. Export


  • Sensitive and Deep Coverage Phosphoproteome Detection Method Reveals Spleen as a More Sensitive Organ than Liver in Early Detection of Liver Fibrosis-Related Signaling Protein Dysregulation

    by Yi Sun, Liying Men, Wenhui Wu, Jinfang Liu, Qi Long, Tao Zuo, Ping Tao, Yudai Yang, Lei Chang, Guibin Wang, et al.

    Although cathepsin S is transported from the spleen to the liver, where it cleaves collagen XVIII to produce endostatin and plays a critical role in the onset of early liver fibrosis, the relationship between liver fibrosis and spleen function remains underexplored. Given the roles of phosphorylation in disease, understanding its regulatory mechanism in early liver fibrosis is crucial. Despite advances in mass spectrometry enhancing phosphoproteomics, its application is limited by small clinical samples and subtle protein changes. We optimized a phosphoproteomic workflow, adjusting the protein amounts and using different enrichment beads and varied mass spectrometers, achieving deep phosphoproteomic coverage from minimal samples. We identified over 46,000 phosphosites in HepG2 cells and over 29,000 phosphosites in mouse liver samples using just 500 μg of proteins. Even with as little as 50 μg of 293T proteins, we detected over 11,000 phosphosites, 1.2 times more than the recently reported RUPE-phospho. Using the Sensitive and Deep Coverage Phosphoproteome Detection method, abbreviated as SDC-PhosDet, we demonstrated that in early liver fibrosis, the spleen exhibits more rapid and sensitive phosphorylation changes than the liver, affecting proteins closely linked to signaling and metabolism such as STAT1, JUN, CBL, ATP7B, and PTPN2. These findings highlight the spleen's role and offer new avenues for investigating the molecular mechanisms of early liver fibrosis, diagnosis, and intervention beyond the liver itself. Moreover, this method holds promise for applying phosphoproteomics to early-stage liver fibrosis using clinical microsamples.


  • Open Access

    Using NAMs to characterize chemical bioactivity at the transcriptomic, proteomic and phosphoproteomic levels

    by Yuan Li, Zhenpeng Zhang, Songhao Jiang, Feng Xu, Liz Tulum, Kaixuan Li, Shu Liu, Suzhen Li, Lei Chang, Mark Liddell, et al.

    Omic-based technologies are of particular interest and importance for non-animal chemical hazard and risk characterization based on the premise that any apical endpoint change must be underpinned by some alterations measured at the omic levels. In this work we studied cellular responses to caffeine and coumarin by generating and integrating multi-omic data from transcriptomic, proteomic and phosphoproteomic experiments. We have shown that the methodology presented here is able to capture the complete chain of events from the first compound-induced changes at the phosphoproteome level to changes in gene expression induced by transcription factors and lastly to changes in protein abundance that further influence changes at the cellular level. In HepG2 cells we found the metabolism of lipids and general cellular stress to be dominant biological processes in response to caffeine and coumarin exposure, respectively. The phosphoproteomic changes were detected early in time, at very low concentrations and provided a fast adaptive cellular response to chemical exposure. Changes in protein abundance were found much less frequently than the transcriptomic changes and can be used, together with the transcriptomic changes, to facilitate a more complete understanding of pathway responses to chemical exposure. GRAPHIC

  • Open Access

    The phosphoproteome is a first responder in tiered cellular adaptation to chemical stress followed by proteomics and transcriptomics alteration

    by Peiru Chen, Yuan Li, Feng Xu, Zhenpeng Zhang, Tao Zuo, Jiabin Guo, Kaixuan Li, Shu Liu, Suzhen Li, Jian Yin, et al.

    Next-generation risk assessment for environmental chemicals and ingredients in consumer products involves a weight of evidence (WoE) framework integrating a suite of new approach methodologies (NAMs) based on points of departure (PoD) obtained from in vitro assays. Omics techniques provide broad coverages of the molecular toxicity pathway space. Transcriptomics assays especially play a leading role by providing relatively conservative PoDs in comparison with apical endpoints. However, it is unclear whether and how parameters measured using other omics technicquesparticipate in the cellular response to chemical perturbations, especially at exposure levels below the transcriptomically defined PoD. Multi-omics coverage may provide additional sensitive or confirmative biomarkers to complement and reduce the uncertainty in safety decisions made using targeted and transcriptomics assays. In the present study, we compared changes in transcriptomics, proteomics and phosphoproteomics with two prototype compounds, coumarin, as a main study and doxorubicin, as a complementary study to understand the sensitivity of the three omics techniques in response to chemically-induced changes in HepG2 and AC16 cells. With measurements obtained for multiple chemical concentrations and time points, we demonstrated that, compared with proteomics and transcriptomics, phosphoproteomics alterations occur not only earlier in time as expected, but also at much lower chemical concentrations and hence are proximal to the very early effects induced by chemical exposure. The phosphoproteomics changes appear to approach maximum when the transcriptomics alterations begin to be initiated. The results are consistent with a tiered framework of cellular response to chemical insults, where posttranslational modification of preexisting proteins is first seen before transcriptomics induction is engaged to launch a more energy-expensive defense that defines a useful PoD. We conclude that as the cost becomes more affordable, proteomics covering posttranslational modifications can be utilized to provide a more complete coverage of chemical-induced cellular alteration and supplement transcriptomics-based health safety decision making.


  • Open Access

    Serum-Derived Exosomal Proteins as Potential Candidate Biomarkers for Hepatocellular Carcinoma

    by Liping Zhao, Jiahui Shi, Lei Chang, Yihao Wang, Shu Liu, Yuan Li, Tao Zhang, Tao Zuo, Bin Fu, Guibin Wang, et al.

    Hepatocellular carcinoma (HCC) is the most common form of hepatic malignancies. The diagnosis of HCC remains challenging due to the low sensitivity and specificity of the diagnostic method. Exosomes, which are abundant in various proteins from parent cells, play pivotal roles in intercellular communication and have been confirmed as promising sources of disease biomarkers. Herein, we performed a simple but robust proteomic profiling on exosomes derived from 1 μL of serum using a data-independent acquisition (DIA) method for the first time, to screen potential biomarkers for the diagnosis of HCC. Ten pivotal differentially expressed proteins (DEPs) (von Willebrand factor (VWF), LGALS3BP, TGFB1, SERPINC1, HPX, HP, HBA1, FGA, FGG, and FGB) were screened as a potential candidate biomarker panel, which could completely discriminate patients with HCC from normal control (NC). Interestingly, Gene Expression Profiling Interactive Analysis (GEPIA) revealed that the expression levels of four genes increased and those of six genes decreased in HCC tissues compared with normal tissues, which were in concordance with protein expression levels. In conclusion, we screened 10 exosomal proteins holding promise for acting as a potential candidate biomarker panel for detection of HCC through a simple but robust proteomic profiling.


  • Quantitative Proteomics Reveals the Development of HBV-Associated Glomerulonephritis Triggered by the Downregulation of SLC7A7

    by Tao Zuo, Peiru Chen, Sha Jing, Tao Zhang, Lei Chang, Feng Xu, Chao Zhao, Ping Xu

    As a hepadnavirus, hepatitis B virus (HBV) can cause damage to extrahepatic organs. The kidney is one of the organs that is more susceptible to damage. Researches on HBV-associated glomerulonephritis (HBV-GN) have been going on for decades. But the underlying molecular mechanism remains obscure. Here, we applied tandem mass tag (TMT) isobaric labelling-based method to quantitatively profile the kidney proteome of HBV transgenic mice to illustrate the pathological mechanisms of HBV-GN. Weighted correlation network analysis (WGCNA), a clustering method for gene expression, is used to cluster proteins. Totally we identified 127 proteins that were highly associated with HBV expression out of a total of 5,169 quantified proteins. Among them, the down-regulated solute carrier (SLC) family proteins are involved in the process of HBV-GN. We also found IL1B was up-regulated in the kidney tissue of HBV transgenic mice. These findings suggest that HBV disrupts the small molecule transport network of the kidney, which contributes to the occurrence of HBV-GN. Transporter, particularly solute carrier family 7 member 7 (SLC7A7), is involved in this process, which might serve as an intervention target for HBV-GN. All MS data have been deposited to the ProteomeXchange Consortium via the iProX partner repository with the dataset identifier PXD016450.